teva glp-1 Diabetes patients now have access to first generic medication: ‘More accessible and affordable’ FDA approval for first generic

Facial serums containing up to 3% TXA for cosmetic purposes are not classified as prescription-only medicines and do not require inclusion in the Australian Register of Therapeutic Goods (ARTG)

Market Expansion and Regulatory Evolution Regulatory bodies are becoming more aware that obesity is a long-term disease that needs medication treatment

The clinical evidence for bee venom acupuncture (BVA) for RA has also been reported (Lee et al

The multifaceted actions of VIP make it a promising target for therapeutic applications in various conditions, such as gastrointestinal disorders, inflammatory diseases, and neurological conditions

Particularly with the expected adoption boost as biosimilars enter the market towards the end of the decade, affordability barriers may begin to crumble, especially in lower-income regions where GLP-1 access currently remains limited